Professor Nicholas Latimer

BSc, MSc, PhD

School of Medicine and Population Health

Professor of Health Economics

Smiling male member of staff in blue checked shirt
Profile picture of Smiling male member of staff in blue checked shirt
n.latimer@sheffield.ac.uk
+44 114 222 0821
Regent Court (ScHARR)

Full contact details

Professor Nicholas Latimer
School of Medicine and Population Health
Regent Court (ScHARR)
30 Regent Street
Sheffield
S1 4DA
Research interests

My research interests focus on economic evaluation methodology, with a particular emphasis on the incorporation of survival analysis within economic models. I am especially interested in the use of causal inference methods to estimate comparative effectiveness in clinical trials confounded by treatment switching, and in observational (or “Big”, or “Real World”) data.

My past research focused primarily on methods for adjusting survival estimates in the presence of treatment switching - that is, when patients in the control group of a clinical trial switch onto the experimental treatment, thus confounding estimates of the treatment effect (where the relevant question for an economic analysis is what would have happened if control group patients did not receive this experimental treatment).

I am currently undertaking a Senior Research Fellowship funded by Yorkshire Cancer Research. During this Fellowship, my focus is on investigating the use of cancer registry datasets to estimate the comparative effectiveness of cancer treatments used in the NHS.

Read privacy notice (Word, 17.2KB)

I also have an active interest in economic evaluations alongside clinical trials, and particularly the incorporation of value of information analysis in feasibility trials.

Publications

Show: Featured publications All publications

Journal articles

  • Latimer N, White IR, Tilling K & Siebert U (2020) . Statistical Methods in Medical Research, 29(10), 2900-2918.
  • Sullivan TR, Latimer NR, Gray J, Sorich MJ, Salter AB & Karnon J (2020) . Value in Health, 23(3), 388-396.
  • Bell Gorrod H, Kearns B, Stevens J, Thokala P, Labeit A, Latimer N, Tyas D & Sowdani A (2019) . Medical Decision Making, 39(8), 899-909.
  • Jackson C, Stevens J, Ren S, Latimer N, Bojke L, Manca A & Sharples L (2017) . Medical Decision Making, 37(4), 377-390.
  • Latimer NR, Abrams KR, Lambert PC, Crowther MJ, Wailoo AJ, Morden JP, Akehurst RL & Campbell MJ (2017) . Statistical Methods in Medical Research, 26(2), 724-751.
  • Latimer NR, Abrams KR, Amonkar MM, Stapelkamp C & Swann RS (2015) . The Oncologist, 20(7), 798-805.
  • Latimer NR (2015) . Expert Review of Pharmacoeconomics & Outcomes Research, 15(4), 561-564.
  • Latimer NR, Carroll C, Wong R, Tappenden P, Venning MC & Luqmani R (2014) . PharmacoEconomics, 32(12), 1171-1183.
  • Latimer NR, Abrams KR, Lambert PC, Crowther MJ, Wailoo AJ, Morden JP, Akehurst RL & Campbell MJ (2014) . Med Decis Making, 34(3), 387-402.
  • Watkins C, Huang X, Latimer N, Tang Y & Wright EJ (2013) . Pharmaceutical Statistics, 12(6), 348-357.
  • Collins M & Latimer N (2013) . BMJ, 346, f1363.
  • Latimer NR (2013) . Med Decis Making, 33(6), 743-754.
  • Morden JP, Lambert PC, Latimer N, Abrams KR & Wailoo AJ (2011) . BMC Med Res Methodol, 11, 4.
  • Latimer N, Lord J, Grant RL, O'Mahony R, Dickson J, Conaghan PG & National Institute for Health and Clinical Excellence Osteoarthritis Guideline Development Group (2009) . BMJ, 339, b2538.

All publications

Journal articles

  • Kang J, Cairns J, Latimer NR, Duffield S & Grieve R (2025) . Value in Health.
  • Petitjean A, Shang H, Bullement A & Latimer N (2025) . Journal of Medical Economics, 28(1), 803-813.
  • Foster M, Clark A, Wild C, Allian F, Turner R, Somers R, Latimer N, Walkinshaw N & Hierons RM (2025) . Journal of Open Source Software, 10(107).
  • Gorrod HB, Mt-Isa S, Xuan J, Vandormael K, Malbecq W, Yorke-Edwards V, White IR & Latimer N (2025) . Statistical Methods in Medical Research, 34(2), 322-335.
  • Xuan J, Mt-Isa S, Latimer N, Bell Gorrod H, Malbecq W, Vandormael K, Yorke-Edwards V & White IR (2025) . Statistical Methods in Medical Research, 34(2), 286-306.
  • Alshreef A, Latimer N, Tappenden P & Dixon S (2025) . Medical Decision Making, 45(1), 60-73.
  • Gibbons CL & Latimer NR (2024) . Value in Health.
  • Hale O & Latimer N (2024) . Value in Health, 27(12), S213-S213.
  • Latimer N (2024) A comparison of the effectiveness of different treatment regimens for pancreatic cancer using English cancer registry data. SCHARR HEDS Discussion Paper(24.05).
  • Latimer NR, Taylor K, Hatswell AJ, Ho S, Okorogheye G, Chen C, Kim I, Borrill J & Bertwistle D (2024) . PharmacoEconomics, 42(12), 1395-1412.
  • Bullement A, Edmondson-Jones M, Guyot P, Welton NJ, Baio G, Stevenson M & Latimer NR (2024) . PharmacoEconomics, 42(12), 1317-1327.
  • Taylor K, Latimer NR, Douglas T, Hatswell AJ, Ho S, Okorogheye G, Borril J, Chen C, Kim I & Bertwistle D (2024) . PharmacoEconomics, 42(11), 1181-1196.
  • Bullement A, Edmondson-Jones M & Latimer N (2024) . BMC Cancer, 24(1).
  • Latimer NR & Rutherford MJ (2024) . PharmacoEconomics, 42, 1073-1090.
  • Chang J-YA, Chilcott JB & Latimer NR (2024) . PharmacoEconomics, 42(5), 487-506.
  • Lally P, Kennedy F, Smith S, Beeken RJ, Buck C, Thomas C, Counsell N, Wyld L, Martin C, Williams S , Roberts A et al (2024) . Cancer Medicine, 13(6).
  • Latimer NR, Dewdney A & Campioni M (2024) . BMC Medical Research Methodology, 24(1).
  • Jennings AC, Rutherford MJ, Latimer NR, Sweeting MJ & Lambert PC (2024) . Value in Health, 27(3), 347-355.
  • Broomfield J, Abrams KR, Freeman S, Latimer N, Rutherford MJ & Crowther MJ (2024) . Statistics in Medicine, 43(1), 184-200.
  • Turner AJ, Sammon C, Latimer N, Adamson B, Beal B, Subbiah V, Abrams KR & Ray J (2024) . PharmacoEconomics, 42(2), 165-176.
  • Lee S, Lambert PC, Sweeting MJ, Latimer NR & Rutherford MJ (2024) . Value in Health, 27(1), 51-60.
  • Bell Gorrod H, White IR, Mt-Isa S, Hmissi A, Vandormael K, Cappoen N & Latimer N (2023) . Value in Health, 26(12), S394-S394.
  • Latimer N, Taylor K, Hatswell A, Ho S, Okorogheye G, Chen C, Kim I, Borrill J & Bertwistle D (2023) . Value in Health, 26(12), S13-S13.
  • Xuan J, Mt-Isa S, Latimer N, Yorke-Edwards V, Vandormael K & White IR (2023) . Value in Health, 26(12), S423-S424.
  • Broomfield J, Crowther M, Freeman S, Abrams K, Latimer N & Rutherford MJ (2023) . Value in Health, 26(12), S421-S422.
  • Taylor K, Latimer N, Hatswell A, Douglas T, Ho S, Okorogheye G, Borrill J, Chen C, Kim I & Bertwistle D (2023) . Value in Health, 26(12), S365-S365.
  • Swaby L, Perry DC, Walker K, Hind D, Mills A, Jayasuriya R, Totton N, Desoysa L, Chatters R, Young B , Sherratt F et al (2023) . Bone & Joint Open, 4(11), 873-880.
  • Broomfield J, Abrams K, Latimer N, Guglieri M, Rutherford M & Crowther M (2023) . Brain and Behavior, 13(12).
  • Sweeting MJ, Rutherford MJ, Jackson D, Lee S, Latimer NR, Hettle R & Lambert PC (2023) . Medical Decision Making, 43(6), 737-748.
  • Bullement A, Stevenson MD, Baio G, Shields GE & Latimer NR (2023) . Medical Decision Making, 43(5), 610-620.
  • Taylor K, Latimer N, Hatswell A, Douglas T, Ho S, Okorogheye G, Borrill J, Chen C, Kim I & Bertwistle D (2023) TREATMENT EFFECT WANING IN IMMUNO-ONCOLOGY HEALTH TECHNOLOGY ASSESSMENTS: A REVIEW OF ASSUMPTIONS AND SUPPORTING EVIDENCE. VALUE IN HEALTH, 26(12), S365-S365.
  • Bullement A, Critchlow S, Stevenson MD, Baio G & Latimer N (2022) A REVIEW OF EXTERNAL EVIDENCE USED TO SUPPORT SURVIVAL EXTRAPOLATION IN ASSESSMENTS OF CANCER DRUGS BY THE NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE (NICE). VALUE IN HEALTH, 25(12), S340-S340.
  • Morga A, Latimer NR, Scott M, Hawkins N, Schlichting M & Wang J (2022) . Value in Health.
  • Nimmo A, Latimer N, Oniscu GC, Ravanan R, Taylor DM & Fotheringham J (2022) . Transplant International, 35.
  • Lally P, Miller N, Roberts A, Beeken RJ, Greenfield DM, Potts HWW, Counsell N, Latimer N, Thomas C, Smith L , Gath J et al (2022) . Pilot and Feasibility Studies, 8(1), 74-74.
  • Gomes M, Latimer N, Soares M, Dias S, Baio G, Freemantle N, Dawoud D, Wailoo A & Grieve R (2022) . PharmacoEconomics, 40(6), 577-586.
  • Latimer NR & Adler AI (2022) . BMJ Medicine, 1.
  • Srivastava T, Latimer NR & Tappenden P (2021) . PharmacoEconomics, 39(8), 869-878.
  • Adler AI & Latimer NR (2021) . JAMA : the Journal of the American Medical Association, 325(20), 2110-2111.
  • Latimer N, Pollard D, Towse A, Henshall C, Sansom L, Ward R, Bruce A & Deakin C (2021) . BMC Health Services Research, 21.
  • Latimer NR, Bhadhuri A, Alshreef AO, Palmer R, Cross E, Dimairo M, Julious S, Cooper C, Enderby P, Brady MC , Bowen A et al (2021) . Clinical Rehabilitation, 35(5), 703-717.
  • Tai T-A, Latimer N, Benedict A, Kiss Z & Nikolaou A (2021) . Value in Health, 24(4), 505-512.
  • Gray J, Sullivan T, Latimer N, Salter A, Sorich M, Ward R & Karnon J (2021) . Medical Decision Making, 41(2), 179-193.
  • Fotheringham J, Latimer N, Froissart M, Kronenberg F, Stenvinkel P, Floege J, Eckardt K-U & Wheeler DC (2021) . Clinical Kidney Journal, 14(2), 665-672.
  • Latimer NR, Towse A & Henshall C (2021) . Expert Review of Pharmacoeconomics & Outcomes Research, 21(3), 331-333.
  • Woods BS, Sideris E, Palmer S, Latimer N & Soares M (2020) . Value in Health, 23(12), 1613-1621.
  • Latimer N, White IR, Tilling K & Siebert U (2020) . Statistical Methods in Medical Research, 29(10), 2900-2918.
  • Palmer R, Dimairo M, Latimer N, Cross E, Brady M, Enderby P, Bowen A, Julious S, Harrison M, Alshreef A , Bradley E et al (2020) . Health Technology Assessment, 24(19), 1-176.
  • Sullivan TR, Latimer NR, Gray J, Sorich MJ, Salter AB & Karnon J (2020) . Value in Health, 23(3), 388-396.
  • Bell Gorrod H, Latimer NR, Damian D, Hettle R, Harty GT & Wong SL (2020) . Advances in Therapy, 17(1), 225-239.
  • Bell Gorrod H, Kearns B, Stevens J, Thokala P, Labeit A, Latimer N, Tyas D & Sowdani A (2019) . Medical Decision Making, 39(8), 899-909.
  • Alshreef A, Latimer N, Tappenden P, Wong R, Hughes D, Fotheringham J & Dixon S (2019) . Medical Decision Making, 39(8), 910-925.
  • Adler AI, Ting S, Dent R & Latimer N (2019) . The Lancet Diabetes & Endocrinology, 7(10), 750-751.
  • Palmer R, Dimairo M, Cooper C, Enderby P, Brady M, Bowen A, Latimer N, Julious S, Cross E, Alshreef A , Harrison M et al (2019) . The Lancet Neurology, 18(9), 821-833.
  • Thomas SA, Drummond AER, Lincoln NB, Palmer RL, das Nair R, Latimer NR, Hackney GL, Mandefield L, Walters SJ, Hatton RD , Cooper CL et al (2019) . Health Technology Assessment, 23(47), 1-176.
  • Ouwens MJNM, Mukhopadhyay P, Zhang Y, Huang M, Latimer N & Briggs A (2019) . PharmacoEconomics, 37(9), 1129-1138.
  • Latimer NR, White IR, Abrams KR & Siebert U (2019) . Statistical Methods in Medical Research, 28(8), 2475-2493.
  • Bell Gorrod H, Latimer NR, Damian D, Hettle R, Harty GT & Wong SL (2019) . Value in Health, 22(7), 772-776.
  • Latimer N, Abrams KR & Siebert U (2019) . BMC Medical Research Methodology, 19.
  • Bullement A, Latimer NR & Bell Gorrod H (2019) . Value in Health, 22(3), 276-283.
  • Whitehurst DGT, Latimer NR, Kagan A, Palmer R, Simmons-Mackie N, Charles Victor J & Hoch JS (2018) . PharmacoEconomics , 2(3), 225-231.
  • Hernandez-Villafuerte K, Fischer A & Latimer NR (2018) . International Journal of Technology Assessment in Health Care, 34(3), 300-316.
  • Latimer NR, Abrams KR, Lambert PC, Morden JP & Crowther MJ (2018) . Statistical Methods in Medical Research, 27(3), 765-784.
  • Ren S, Minton J, Whyte S, Latimer N & Stevenson M (2017) . Value in Health, 20(9), a758-a758.
  • Jackson C, Stevens J, Ren S, Latimer N, Bojke L, Manca A & Sharples L (2017) . Medical Decision Making, 37(4), 377-390.
  • Latimer NR, Abrams KR, Lambert PC, Crowther MJ, Wailoo AJ, Morden JP, Akehurst RL & Campbell MJ (2017) . Statistical Methods in Medical Research, 26(2), 724-751.
  • Skaltsa K, Ivanescu C, Naidoo S, Phung D, Holmstrom S & Latimer NR (2017) . Targeted Oncology, 12(1), 111-121.
  • Henshall C, Latimer NR, Sansom L & Ward RL (2016) . International Journal of Technology Assessment in Health Care, 32(3), 167-174.
  • Latimer NR, Henshall C, Siebert U & Bell H (2016) . International Journal of Technology Assessment in Health Care, 32(3), 160-166.
  • Thomas SA, Coates E, das Nair R, Lincoln NB, Cooper C, Palmer R, Walters SJ, Latimer NR, England TJ, Mandefield L , Chater T et al (2016) . Pilot and Feasibility Studies, 2(1).
  • Hatswell AJ, Porter J, Lee D, Hertel N & Latimer NR (2016) . Value in Health, 19(8), 1055-1058.
  • Diaz J, Sternberg CN, Mehmud F, Delea TE, Latimer N, Pandite L & Motzer RJ (2016) . Oncology, 90(3), 119-126.
  • Naidoo S, Ivanescu C, Skaltsa K, Phung D, Holmstrom S & Latimer N (2015) . Value in Health, 18(3).
  • Palmer R, Cooper C, Enderby P, Brady M, Julious S, Bowen A & Latimer N (2015) . Trials, 16.
  • Latimer NR, Abrams KR, Amonkar MM, Stapelkamp C & Swann RS (2015) . The Oncologist, 20(7), 798-805.
  • Latimer NR (2015) . Expert Review of Pharmacoeconomics & Outcomes Research, 15(4), 561-564.
  • Latimer NR, Amonkar MM, Stapelkamp C & Sun P (2015) . Melanoma Research, 25(6), 528-536.
  • Whitehurst DGT, Latimer NR, Kagan A, Palmer R, Simmons-Mackie N & Hoch JS (2015) . Aphasiology, 29(7), 763-780.
  • Latimer NR, Carroll C, Wong R, Tappenden P, Venning MC & Luqmani R (2014) . PharmacoEconomics, 32(12), 1171-1183.
  • Angus C, Latimer N, Preston L, Li J & Purshouse R (2014) . Frontiers in Psychiatry, 5, 114.
  • Nicholson KG, Abrams KR, Batham S, Medina MJ, Warren FC, Barer M, Bermingham A, Clark TW, Latimer N, Fraser M , Perera N et al (2014) . Health Technol Assess, 18(36), 1-viii.
  • Latimer NR, Abrams KR, Lambert PC, Crowther MJ, Wailoo AJ, Morden JP, Akehurst RL & Campbell MJ (2014) . Med Decis Making, 34(3), 387-402.
  • Goyder E, Hind D, Breckon J, Dimairo M, Minton J, Everson-Hock E, Read S, Copeland R, Crank H, Horspool K , Humphreys L et al (2014) . Health Technol Assess, 18(13), 1-210.
  • Latimer NR (2014) . Med Decis Making, 34(3), 279-282.
  • Latimer NR, Dixon S & Palmer R (2013) . Int J Technol Assess Health Care, 29(4), 402-409.
  • Watkins C, Huang X, Latimer N, Tang Y & Wright EJ (2013) . Pharmaceutical Statistics, 12(6), 348-357.
  • Latimer N, Dixon S, Drahota AK & Severs M (2013) . Age Ageing, 42(5), 641-645.
  • Collins M & Latimer N (2013) . BMJ, 346, f1363.
  • Purshouse RC, Brennan A, Rafia R, Latimer NR, Archer RJ, Angus CR, Preston LR & Meier PS (2013) . Alcohol Alcohol, 48(2), 180-188.
  • Whitehurst DGT & Latimer NR (2013) . Medical Acupuncture, 25(1), 2-4.
  • Latimer NR (2013) . Med Decis Making, 33(6), 743-754.
  • Latimer NR, Bhanu AC & Whitehurst DGT (2012) . Acupuncture in Medicine, 30(3), 182-186.
  • Palmer R, Enderby P, Cooper C, Latimer N, Julious S, Paterson G, Dimairo M, Dixon S, Mortley J, Hilton R , Delaney A et al (2012) . Stroke, 43(7), 1904-1911.
  • Mulhern B, Rowen D, Jacoby A, Marson T, Snape D, Hughes D, Latimer N, Baker GA & Brazier JE (2012) . Epilepsy and Behavior, 24(1), 36-43.
  • Latimer N, Lord J, Grant RL, O'Mahony R, Dickson J & Conaghan PG (2011) . Pharmacoeconomics, 29(3), 225-237.
  • Morden JP, Lambert PC, Latimer N, Abrams KR & Wailoo AJ (2011) . BMC Med Res Methodol, 11, 4.
  • Latimer N (2009) . Acupunct Med, 27(2), 72-75.
  • Latimer N, Lord J, Grant RL, O'Mahony R, Dickson J, Conaghan PG & National Institute for Health and Clinical Excellence Osteoarthritis Guideline Development Group (2009) . BMJ, 339, b2538.
  • Barham L, Lewis D & Latimer N (2007) . Sex Transm Infect, 83(6), 441-446.
  • Campbell H, Latimer N, Jansen JP & Cope S () . Statistical Methods in Medical Research.
  • Latimer NR, Bell H, Abrams KR, Amonkar MM & Casey M () . Cancer Medicine.
  • Goyder EC, Maheswaran R & Read S () . Journal of Public Health.

Book chapters

  • Jackson C, Latimer N, Jansen J, Pechlivanoglou P & Baio G (2025) , R for Health Technology Assessment (pp. 168-202). Chapman and Hall/CRC

Conference proceedings

  • Chang JYA, Rex SS, Chilcott JB & Latimer NR (2024) . Value in Health, Vol. 27(12) (pp S450-S450)
  • Hale O & Latimer N (2024) THE HAZARDS OF APPLYING HAZARD RATIOS TO ACCELERATED FAILURE TIME MODELS: A SIMULATION STUDY. VALUE IN HEALTH, Vol. 27(12) (pp S213-S213)
  • Chang JYA, Rex SS, Chilcott JB & Latimer NR (2024) ENHANCED RANDOMISED CONTROLLED TRIALS-REAL- WORLD EVIDENCE (RCT-RWE) AGREEMENT ASSESSMENT METRICS FOR HEALTH TECHNOLOGY ASSESSMENT (HTA). VALUE IN HEALTH, Vol. 27(12)
  • Chang JYA, Rex SS, Chilcott JB & Latimer NR (2024) ENHANCED RANDOMISED CONTROLLED TRIALS-REAL-WORLD EVIDENCE (RCT-RWE) AGREEMENT ASSESSMENT METRICS FOR HEALTH TECHNOLOGY ASSESSMENT (HTA). VALUE IN HEALTH, Vol. 27(12)
  • Latimer N, Taylor K, Hatswell A, Ho S, Okorogheye G, Chen C, Kim I, Borrill J & Bertwistle D (2023) TESTING A SURVIVAL EXTRAPOLATION ALGORITHM FOR CANCER IMMUNOTHERAPIES: PASS OR FAIL?. VALUE IN HEALTH, Vol. 26(12) (pp S13-S13)
  • Gorrod BH, White IR, Mt-Isa S, Hmissi A, Vandormael K, Cappoen N & Latimer N (2023) ADJUSTING FOR SWITCHES TO MULTIPLE TREATMENTS IN RANDOMISED CONTROLLED TRIALS: A COMPARISON OF INVERSE PROBABILITY WEIGHTING AND TWO-STAGE ESTIMATION METHODS. VALUE IN HEALTH, Vol. 26(12) (pp S394-S394)
  • Xuan J, Mt-Isa S, Latimer N, Yorke-Edwards V, Vandormael K & White IR (2023) EVALUATING BIAS ASSOCIATED WITH INADEQUATE VARIABLE SELECTION WHEN USING INVERSE PROBABILITY OF CENSORING WEIGHTS TO ADJUST FOR TREATMENT SWITCHES IN CLINICAL TRIALS. VALUE IN HEALTH, Vol. 26(12) (pp S423-S424)
  • Broomfield J, Crowther M, Freeman S, Abrams K, Latimer N & Rutherford MJ (2023) ACCOUNTING FOR STUDY HETEROGENEITY WHEN MODELLING THE MULTI-STATE NATURAL HISTORY OF RARE DISEASES. VALUE IN HEALTH, Vol. 26(12) (pp S421-S422)
  • Rex S, Chang JY, Bradburn M, Akehurst R & Latimer N (2022) . Value in Health, Vol. 25(12). Vienna, 6 November 2022 - 6 November 2022.
  • Kennedy F, Miller N, Roberts A, Beeken RJ, Greenfield D, Potts HWW, Counsell N, Latimer N, Thomas C, Smith L , Gath J et al (2022) . Psycho-Oncology, Vol. 31(S2) (pp 20-20). Online, 28 April 2022 - 28 April 2022.
  • Alshreef A, Latimer N, Tappenden P, McKane W, Fotheringham J & Dixon S (2022) A CASE STUDY ASSESSING THE COST-EFFECTIVENESS OF MAINTENANCE IMMUNOSUPPRESSIVE THERAPY FOR KIDNEY TRANSPLANTATION IN ADULTS: ACCOUNTING FOR NON-ADHERENCE USING DATA FROM A RANDOMISED TRIAL AND THE REAL WORLD WITHIN A DECISION-ANALYTIC MODEL. VALUE IN HEALTH, Vol. 25(7) (pp S529-S529)
  • Alshreef A, Latimer N, Tappenden P, McKane W, Hughes DA & Dixon S (2022) A METHODOLOGICAL FRAMEWORK TO ACCOUNT FOR THE IMPACT OF NON-ADHERENCE ON THE COST-EFFECTIVENESS OF CHRONIC MEDICATIONS. VALUE IN HEALTH, Vol. 25(7) (pp S520-S520)
  • Srivastava T, Latimer NR & Tappenden P (2020) ESTIMATION OF TRANSITION PROBABILITIES FOR STATE-TRANSITION MODELS: A REVIEW OF NICE APPRAISALS. VALUE IN HEALTH, Vol. 23 (pp S615-S616)
  • Amy J-YC, Latimer NR, Gillespie D & Chilcott J (2020) PREVALENCE, CHARACTERISTICS AND KEY ISSUES OF MODELLING TREATMENT SEQUENCES IN HEALTH ECONOMIC EVALUATIONS: A SYSTEMATIC REVIEW OF NICE TECHNOLOGY APPRAISALS. VALUE IN HEALTH, Vol. 23 (pp S606-S606)
  • Latimer N, White I, Tilling K & Siebert U (2020) ESTIMATING THE TRUE VALUE OF NEW ONCOLOGY TREATMENTS: IMPROVED TWO-STAGE ESTIMATION TO ADJUST FOR TREATMENT SWITCHING IN RANDOMISED TRIALS. MEDICAL DECISION MAKING, Vol. 40(1) (pp E294-E295)
  • Tai TA, Latimer NR, Benedict Á, Kiss Z & Nikolaou A (2019) . Value in Health, Vol. 22 (pp S464-S464)
  • Fotheringham J, Latimer N, Froissart M, Kronenburg F, Stenvinkel P, Floege J, Eckardt K-U & Wheeler D (2019) . Nephrology Dialysis Transplantation, Vol. 34(Supplement_1)
  • Fotheringham J, Latimer N, Froissart M, Kronenburg F, Stenvinkel P, Floege J, Eckardt K-U & Wheeler D (2019) THE ASSOCIATION BETWEEN FOUR TIMES A WEEK COMPARED TO THREE TIMES A WEEK HAEMODIALYSIS AND SURVIVAL, HOSPITALISATION AND VASCULAR ACCESS COMPLICATIONS IN EUROPEAN IN-CENTRE PATIENTS. NEPHROLOGY DIALYSIS TRANSPLANTATION, Vol. 34
  • Tai TA, Latimer NR, Benedict A, Kiss Z & Nikolaou A (2019) IMPACT OF USING IMMATURE SURVIVAL DATA ON NICE DECISION-MAKING. VALUE IN HEALTH, Vol. 22 (pp S464-S464)
  • O'Brien S, Cork L, Bandeira V, Bescoby R, Foroni L, Alaily L, Osborne W, Bell-Gorrod H, Latimer N, Apperley J , Hedgley C et al (2018) . Blood, Vol. 132(Supplement 1) (pp 457-457)
  • Muresan B, Mamolo CM, Cappelleri JC, Mokgokong R, Palaka A, Hills RK, Latimer N & Heeg B (2018) . Blood, Vol. 132(Supplement 1) (pp 2712-2712)
  • Alshreef A, Latimer N, Tappenden P, McKane W, Wong R, Hughes D, Wailoo A, White I, Fotheringham J & Dixon S (2018) Adjusting the causal effects of treatments in the presence of patient non-adherence: a systematic review of methodological papers. European Society for Patient Adherence, Compliance and Persistence, Dublin, 29 November 2018 - 29 November 2018.
  • Latimer NR (2018) . Value in Health, Vol. 21 (pp S68-S68)
  • Bell Gorrod H, Latimer N, Damian D, Hettle R, Harty GT & Wong SL (2017) . Value in Health, Vol. 20(9) (pp A769-A769)
  • Bell Gorrod H, Latimer N, Damian D, Hettle R, Harty GT & Wong SL (2017) . Value in Health, Vol. 20(9) (pp A718-A718)
  • Latimer N & Abrams KR (2017) . Value in Health, Vol. 20(5) (pp A314-A314). Boston, USA, 20 May 2017 - 20 May 2017.
  • Thomas SA, Drummond A, Lincoln NB, Palmer R, dasnair R, Latimer N, Hackney G, Hatton R, Walters S, Mandefield L , Cooper C et al (2017) Behavioural activation therapy for depression after stroke (BEADS): a feasibility randomised controlled pilot trial of a psychological intervention for post-stroke depression. INTERNATIONAL JOURNAL OF STROKE, Vol. 12 (pp 15-15)
  • Gorrod BH, Latimer N, Damian D, Hettle R, Harty GT & Wong SL (2017) ADJUSTING FOR TREATMENT SWITCHING IN THE RELAPSING-REMITTING MULTIPLE SCLEROSIS CLARITY TRIAL AND THE CLARITY EXTENSION STUDY. VALUE IN HEALTH, Vol. 20(9) (pp A718-A718)
  • Watkins CL, Latimer N, Wang J & Wright EJ (2016) . Value in Health, Vol. 19(7) (pp A398-A398)
  • Bell H, Latimer N, Amonkar M & Swann S (2015) . Value in Health, Vol. 18(7) (pp A338-A338)
  • Diaz J, Sternberg CN, Mehmud F, Delea TE, Latimer N, Bartlett-Pandite AN & Motzer R (2015) . Journal of Clinical Oncology, Vol. 33(15_suppl) (pp e15592-e15592)
  • Bell H, Latimer N, Amonkar M & Casey M (2014) . Value in Health, Vol. 17(7) (pp A577-A577)
  • Latimer N, Amonkar M, Stapelkamp C & Sun P (2014) . Cancer Research, Vol. 74(19_Supplement) (pp CT330-CT330)
  • Boucher R, Abrams KR, Crowther MJ, Lambert PC, Wailoo AJ & Latimer NR (2013) . VALUE IN HEALTH, Vol. 16(7) (pp A610-A611)
  • Latimer NR, Abrams KR, Lambert PC, Crowther MJ, Wailoo AJ, Morden JP, Akehurst RL & Campbell MJ (2013) . VALUE IN HEALTH, Vol. 16(7) (pp A325-A325)
  • Latimer N, Abrams KR, Amonkar M, Stapelkamp C & Swann RS (2013) Adjusting for treatment crossover in the BREAK-3 metastatic melanoma trial for dabrafenib: Preliminary analysis. JOURNAL OF CLINICAL ONCOLOGY, Vol. 31(15)
  • Abrams KR, Latimer N, Amonkar M, Stapelkamp C & Casey M (2013) Adjusting for treatment crossover in the METRIC metastatic melanoma (MM) trial for trametinib: Preliminary analysis. JOURNAL OF CLINICAL ONCOLOGY, Vol. 31(15)
  • Paracha N, Davies A, Latimer N, Parker C, Mealing S, Scott D, Padhiar A, Schulpher M & Wang Q (2013) The importance of adjusting for treatment crossover bias in oncology clinical trials: An analysis of the EGF104900 trial in metastatic breast cancer (mBC). JOURNAL OF CLINICAL ONCOLOGY, Vol. 31(15)
  • Latimer N, Lambert P, Crowther M, Abrams KR, Wailoo AJ & Morden JP (2012) . VALUE IN HEALTH, Vol. 15(7) (pp A462-A462)
  • Latimer N (2011) . VALUE IN HEALTH, Vol. 14(7) (pp A242-A242)
  • Rowen D, Mulhern B, Brazier J, Jacoby A, Marson T, Latimer N, Snape D, Baker G & Hughes D (2010) Using the Liverpool Quality of Life battery to develop a health state classification system for Epilepsy. QUALITY OF LIFE RESEARCH, Vol. 19 (pp 57-57)
  • Gyldmark M, Gatzemeier U, Nicolson M, Latimer N & Walzer S (2008) EXPLORATORY ECONOMIC EVALUATION OF ADJUVANT TREATMENT OF NON-SMALL-CELL LUNG CANCER (NSCLC) WITH BEVACIZUMAB IN ADDITION TO A CISPLATIN-BASED TREATMENT REGIMEN IN THE UNITED KINGDOM. VALUE HEALTH, Vol. 11(6) (pp A357-A357)
  • Ducournau P, Latimer N, Sabate E & Walzer S (2008) EXPLORATORY COST EFFECTIVENESS ANALYSIS OF BEVACIZUMAB IN ADDITION TO FOLFOX-4 IN THE ADJUVANT TREATMENT OF STAGE III COLON CANCER: A UK PERSPECTIVE. VALUE HEALTH, Vol. 11(6) (pp A471-A472)
  • Latimer N & Lewis G (2008) The cost of adults with severe active rheumatoid arthritis who do not respond to treatment following treatment with one TNF inhibitor. RHEUMATOLOGY, Vol. 47 (pp II123-II124)
  • Somerville M, Scott D, Hancock M, Geary U & Latimer N (2008) The impact of rituximab on resource use in a UKNHS rheumatology day care service. RHEUMATOLOGY, Vol. 47 (pp II119-II120)
  • Latimer N & Lewis G (2008) What are the costs of treating severe active rheumatoid arthritis with TNF inhibitors, rituximab and abatacept?. RHEUMATOLOGY, Vol. 47 (pp II122-II123)
  • Latimer NR & Lewis GJ (2005) A cost utility analysis of peginterferon alfa-2a (40KD) versus peginterferon alfa-2b (12KD) for the treatment of chronic hepatitis C (CHC) in the UK. VALUE HEALTH, Vol. 8(6) (pp A58-A58)

Reports

  • Chang J-YA, Chilcott JB & Latimer NR (2024) Leveraging real-world data to assess treatment sequences in health economic evaluations: a study protocol for emulating target trials using the English Cancer Registry and US Electronic Health Records-Derived Database
  • Latimer N & Pollard D (2019) Pre-read document 1 : challenges in valuing and paying for combination regimens in oncology
  • Latimer NR, White IR, Abrams KR & Sieburt U (2017) Causal inference for long-term survival in randomised trials with treatment switching: Should re-censoring be applied when estimating counterfactual survival times?
  • Latimer NR, Abrams KR, Lambert PC, Crowther MJ & Morden JP (2014) Assessing methods for dealing with treatment crossover in clinical trials: A follow-up simulation study

Posters

  • Bell H, Latimer N, Amonkar M & Casey M Adjusting for treatment crossover in a trametinib metastatic melanoma RCT: Identifying the appropriate method.

Preprints

  • Gupta A, Latimer N, Gomes M, Chan K, Kent S, Duffield S, Ramagopalan S, Bendavid E, Cheung W, Subbiah V & Arora P (2025) , Cold Spring Harbor Laboratory.
  • Lally P, Miller N, Roberts A, Beeken RJ, Greenfield DM, Potts HWW, Counsell N, Latimer N, Thomas C, Smith L , Gath J et al (2021) , Springer Science and Business Media LLC.
Teaching interests

My teaching interests lie in the field of health economics, economic evaluation and survival analysis. I have previously co-ordinated and taught several modules on economic evaluation and survival analysis on various MSc courses. Currently, I teach methods for adjusting for treatment switching in clinical trials on the Further Statistical Methods for Health Economic Analysis module on the Health Economics and Decision Modelling MSc.

I have completed the Certificate in Learning and Teaching (PGCertHE), the University Of Sheffield's professional development course in learning and teaching in higher education.

I am currently supervising five PhD students. Abu Alshreef is investigating adjustment for non-adherence in economic evaluation. Rachid Rafia is exploring multi-state models and partitioned survival models for cancer treatments. Amy Chang is researching methods for modelling the effectiveness and cost-effectiveness of treatment sequences. Ash Bullement is investigating survival analysis methods. Saleema Rex is examining the use of causal inference methods to estimate comparative effectiveness using registry datasets.

I am interested in supervising potential students on topics around adjustment for treatment switching in clinical trials, and the use of causal inference methods to estimate comparative effectiveness from observational datasets.

Professional activities and memberships

I have pursued my research interests through a series of research fellowships. In 2012 I completed an NIHR Doctoral Research Fellowship, and in 2018 I completed an NIHR Post-Doctoral Research Fellowship. My current 5-year Yorkshire Cancer Research Fellowship began in January 2019. I also contribute to several other research and consultancy projects in ScHARR.

  • I am a member of NICE Technology Appraisal Committee B
  • I have been a member of the Yorkshire and Humber Research for Patient benefit Programme Regional Advisory committee
  • I am a member of the Health Economists Study Group
  • I am a Fellow of the Higher Education Academy
  • I have been an invited expert for the NICE Scientific Advice Programme.
Downloads

Links